

AD_____

Award Number: DAMD17-00-1-0676

TITLE: Concurrent and Independent Genetic Alterations in
Epithelial and Stromal Components of Breast Neoplasms:
Implication for Tumor Development and Progression

PRINCIPAL INVESTIGATOR: Fatteneh A. Tavassoli, Ph.D.
Yan-gao Man, M.D., Ph.D.

CONTRACTING ORGANIZATION: American Registry of Pathology
Rockville, Maryland 20849-0008

REPORT DATE: October 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20020206 121

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 074-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE October 2001	3. REPORT TYPE AND DATES COVERED Final (30 Sep 00 - 30 Sep 01)	
4. TITLE AND SUBTITLE Concurrent and Independent Genetic Alterations in Epithelial and Stromal Components of Breast Neoplasms: Implication for Tumor Development and Progression		5. FUNDING NUMBERS DAMD17-00-1-0676	
6. AUTHOR(S) Fatteneh A. Tavassoli, Ph.D. Yan-gao Man, M.D., Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) American Registry of Pathology Rockville, Maryland 20849-0008 E-Mail: tavassol@afip.osd.mil		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Report contains color			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) <p>Our previous study on paraffin embedded tissues from patients with mammary carcinomas revealed a high frequency of loss of heterozygosity (LOH) in microdissected epithelial (EP) and adjacent or distant stromal (ST) cells. This study attempts to confirm previous findings on a larger scale and in a wider spectrum. Immunohistochemical and genetic analyses were performed on malignant and benign EP lesions with and without distinct ST alterations. Our findings show that morphologically comparable ST cells associated with malignant and benign lesions display a substantially different immunostaining patterns with antibodies to cell proliferation associated proteins, blood vessel components, and extracellular matrix molecules, and also show different frequencies and patterns of LOH at multiple chromosomal loci. ST cells from neither malignant nor benign lesions, however, display LOH or microsatellite instability with multiple DNA markers at chromosome 17p. These results are consistent with those of our previous studies, suggesting that [1] morphologically comparable ST cells in malignant and benign lesions are biofunctionally and genetically different and their genetic alterations correlate with those in their EP counterparts; 2] the biofunctions of ST cells may be independent of p53 gene regulation.</p>			
14. SUBJECT TERMS Breast Cancer; Concurrent and independent genetic alterations; Epithelium - stroma interactions; Tumor development and progression		15. NUMBER OF PAGES 32	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	6
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusions.....	10
References.....	11
Appendices.....	12

Introduction

A dynamic, reciprocal interaction between epithelial (EP) and mesenchymal (stromal) cells during embryogenesis is a well-recognized phenomenon, which determines the pattern and extent of the EP morphogenesis and cytodifferentiation (1-3). Recent studies have suggested that a similar interaction may also take place during the development and progression of mammary tumors (4-6). The molecular mechanism and detailed process of EP-stromal (ST) interactions during both neonatal and adult stages, however, have not been well elucidated. In addition, although a number of genetic alterations, including gene mutations, microsatellite instability (MI), and loss of heterozygosity (LOH), have been consistently detected in the EP component of both pre-malignant and malignant mammary lesions (7-9), the genetic profile of the ST component in these lesions remains essentially unexplored.

In a previous study (10), we evaluated the genetic profile of a type of “non-hyperplastic” flat intraductal carcinoma, also known as “clinging ductal carcinoma *in situ*”, which is characterized by a single layer of mildly to severely atypical cells simply replacing the single layer of the native EP cells without appreciable proliferative or architectural alterations. In that study, morphologically normal ST cells at a distance (at least 15mm) from the EP component were microdissected to serve as normal internal controls. The ST cells in 22 of 25 (88%) cases displayed no genetic abnormality, while the ST cells in 3 cases (12%) showed LOH at multiple chromosomal loci. Those cases were excluded from that study because at that time we could not find adequate explanation in the literature. This surprising finding of LOH in ST cells prompted the initiation of a more detailed study. Paraffin embedded breast tissues from 11 female patients with intraductal or with invasive ductal carcinoma (IDC), and from 10 reduction mammoplasty specimen from normal women without radiological, or clinical and histopathological abnormality in their breasts, were selected for assessment of LOH. In each case, the normal appearing ST element (mainly fibroblasts, adipocytes, lymphocytes, and blood vessels) at a distance (at least 15mm) from, and close to the EP component, along with phenotypically different EP cells, were separately microdissected and placed in different tubes. The frequency and pattern of LOH among microdissected cells were compared after PCR amplification with a total of 12 DNA markers at

chromosomes 2p, 3p, 11q, 16q, and 17q. The LOH frequency in ST cells close to EP tumor cells ranged from 10-65% in intraductal carcinoma and from 20-75% in IDC. Furthermore, 10 of the 12 (83%) DNA markers showed LOH in the ST cells at a distance, ranging from 11-57 % of informative cases. In each case, the pattern and frequency of LOH in malignant EP cells were very similar to those in the ST component, and the EP and ST components in 8 (73%) of 11 cases displayed at least one identical LOH. In contrast, the frequency of LOH in clear-cut normal EP cells (33% or 4 of 12 markers) was substantially lower than that in normal appearing ST cells (83% or 10 of 12 markers) in cases with carcinoma. No LOH was detected in either EP or ST cells of the 10 reduction mammoplasty specimen used as normal controls. This study revealed a high frequency of LOH in normal appearing ST cells for the first time, suggesting that ST cells might be concurrently involved in the development or progression of mammary carcinomas, and that genetic alterations in ST cells may precede those in their EP counterparts. The manuscript of this study was published, with "highest priority", in Cancer Research (11), one of the most prestigious research journals.

The current study attempts to confirm our previous one using a larger number of cases and a wider spectrum of lesions. More importantly, as it has been suggested that the evolution and progression of human mammary carcinoma involves a sequential, multistep process, starting from transformation of normal cells to hyperplastic, then to *in situ*, and eventually to invasive and metastatic lesions, this study attempted to assess the correlation between EP and ST cells during various steps of the hypothesized multistep process of carcinogenesis. The hypothesis to be tested is that the ST component of a majority of mammary carcinomas plays a crucial role in preparing a receptive microenvironment for tumor development and progression, or more remotely both the EP and ST components are derived through a clonal growth of a common progenitor sharing a common immunohistochemical and genetic profile. The identification of genetic abnormalities in ST cells could facilitate the disclosure of the mechanism of the development and progression of EP tumors, and also might lead to the development of novel therapeutic modalities that specifically target ST cells, rather than the EP component of breast cancer.

Body (Materials and Methods)

The original purpose stated that: "The test will be accomplished by comparing the frequency and pattern of LOH, as well as the clonality between EP and ST cells. The test will compare carcinoma and benign lesions characterized by a distinctive stromal alteration with carcinomas and benign lesions lacking a distinctive stromal change, to determine:

- [1] whether the EP cells and their surrounding ST cells display a similar frequency and pattern of LOH, and the same clonality;
- [2] whether the frequency and pattern of LOH correlates with the EP phenotype;
- [3] whether there is shared LOH in various patterns of intraepithelial neoplasms and invasive carcinomas" (see attached Appendix A)

To address these three issues, three corresponding experiments have been conducted:

- [1] Paraffin embedded tissues from a total of 20 female patients with bilateral breast cancer had been retrieved from our files and processed for immunohistochemical and genetic analyses
- [2] Paraffin embedded tissues from a total of 20 female patients with tubular carcinoma, which is a malignant lesion characterized by distinctive stromal alterations, and from 16 patients with infiltrating syringomatous adenoma, which is a benign lesion also characterized by distinctive stromal alterations, were retrieved from our files and processed for immunohistochemical and genetic analyses, including LOH and clonality analysis
- [3] Paraffin embedded tissues from a total of 125 patients with various patterns of intraepithelial neoplasms and invasive carcinomas had been retrieved from our files and processed for immunohistochemical and genetic analyses.

Key research accomplishments

The original purpose listed the following five experimental procedures or objectives to accomplish the purposed project:

- [1] Immunostaining sections with specific antibodies to highlight EP and ST cells;
- [2] Microdissection of each EP phenotype and its surrounding stroma;
- [3] DNA extraction from microdissected samples;
- [4] PCR amplification of DNA extracts with fluorescent dye-labeled markers;
- [5] Electrophoresis of PCR products and detection of signals with an automated DNA sequencer (see attached Appendix A).

All the listed procedures or objectives have been accomplished and the corresponding results have been analyzed prior to September 30, 2001.

Reportable outcomes

The main reportable outcomes can be summarized as follows:

- [1]. EP tumor cells and their surrounding and distant ST cells display both concurrent and independent LOH at multiple chromosomal loci, while concurrent alterations are more frequently seen.
- [2]. LOHs detected in ST cells appear to be clustered at chromosomes 3p, 11p, and 16q, but are rarely seen at chromosome 17p
- [3]. Comparative genomic hybridization (CGH) analysis reveals an identical change, deletion of 13q, in both the EP and ST component of a cancerous breast.
- [4]. Our preliminary studies reveal that the EP and ST component in some cases share the same clonality
- [5]. Morphologically comparable ST cells associated with benign and malignant EP lesions display different immunohistochemical and genetic profiles, closely correlating with their EP counterparts.
- [6]. The status of estrogen receptor (ER) expression in EP cells of intraepithelial neoplasms is closely associated with the integrity of the subjacent myoepithelial cell layer and the basement membrane.

For each of the three experiments corresponding to the three issues addressed in the proposal, the laboratory findings have been summarized, an abstract has been submitted to scientific conferences, and a manuscript is under preparation, which will be sent for publication in late 2001 or early 2002. The titles and the status of the three abstracts are as follows:

- [1] Primary bilateral breast cancers display different LOH and CGH profiles in both epithelial and stromal components.** Accepted for podium presentation at the 24th Annual San Antonio Breast Cancer Symposium" (see attached Appendix B).
- [2] Morphologically comparable stromal cells associated with benign and malignant mammary epithelial lesions show different immunohistochemical and genetic profiles.** Submitted to the 2002 Annual Meeting of US & Canadian Academy of Pathology (see attached Appendix C).
- [3] Focal loss of estrogen receptor (ER) expression in ER positive ductal intraepithelial neoplasia is associated with disruption of the immediate subjacent myoepithelial cell layer.** Submitted to

the 2002 Annual Meeting of US & Canadian Academy of Pathology (see attached Appendix D).

In addition, since this project required a great number of electrophoresis for PCR amplified products, an innovated protocol, which permits a significant reduction in electrophoresis time and reagent costs was developed in our Laboratory. The manuscript of this protocol has been published in **Electrophoresis 22:1915-1919, 2001**, a Med-Line listed journal (see attached Appendix E).

Conclusions

The frequency and pattern of LOH seen in our current study are consistent with those of our previous study (11). These findings appear to be sufficient and adequate to make a conclusion for each of the three questions addressed in our proposal (see attached Appendix A):

- [1] The EP cells and their surrounding ST cells display a similar frequency and pattern of LOH, and the same clonality.
- [2] The frequency and pattern of LOH correlates with the EP phenotype;
- [3] There is shared LOH in various patterns of intraepithelial neoplasms and invasive carcinomas.

In addition, this study has expanded the spectrum of our previous findings in several respects:

- [1]. For the first time, CGH analysis was performed in both EP and ST cells, and an identical CGH change was identified in both the EP and ST cells of a cancerous breast
- [2]. Both the immunohistochemical and genetic profiles in morphologically comparable ST cells associated with benign and malignant EP lesions were assessed, and substantial differences were observed in these ST cells
- [3]. Several chromosomal loci that display high frequencies of LOH in ST cells have been identified.

These findings appear to support our hypothesis that the EP and ST components of a majority of mammary carcinomas are derived through a clonal growth of a common progenitor. Even if the EP and ST cells were independently derived, the genetic and biofunctional alterations involved in carcinogenesis appear to result from dynamic, reciprocal interactions between the ST and EP cells. Ultimately, these findings suggest that ST cells play an important role in both the development and progression of the EP tumors. The elucidation of the mechanism and detailed process of these interactions may substantially facilitate the disclosure of the mechanism of the development and progression of epithelial tumors, and may also lead to development of novel therapeutic modalities that specifically target ST cells, rather than the EP component of breast cancer.

References

1. Dunbar ME, Young P, Zhang JP, et al. Stromal cells are critical targets in the regulation of mammary ductal morphogenesis by parathyroid hormone-related protein. *Dev Biol* 203:75-89, 1998
2. Wiesen JF, Young P, Werb Z, Cunha GR. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. *Development* 126:335-344, 1999
3. Humphres RC, Lydon J, O'Malley BW, Rosen JM. Mammary gland is mediated by both stromal and epithelial progesterone receptors. *Mol Endocrinol* 11:801-811, 1997
4. Lochter A. Plasticity of mammary epithelia during normal development and neoplastic progression. *Biochem Cell Biol* 76:997-1008, 1998
5. Sternlicht MA, Lochter A, Sympson CJ, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. *Cell* 98:137-146, 1999
6. Guarino M, Micheli P, Pallotti F, Giordano F. Pathological relevance of epithelial and mesenchymal phenotype plasticity. *Pathol Res Pract* 195:379-389, 1999
7. Done SJ, Arneson NC, Ozcelik H, et al. P53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. *Cancer Res* 58:785-789, 1998
8. Patel U, Grundfest-Broniatowski S, Gupta M, Banerjee S. Microsatellite instabilities at five chromosomes in primary breast tumors. *Oncogene* 9:3695-3700, 1994
9. Linger RA, Fujii H, Man YG, Gabrielson E, Tavassoli FA. Comparison of loss of heterozygosity in primary and recurrent ductal carcinoma in situ of the breast. *Mod Pathol* 10:1151-1159, 1998
10. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"). *Cancer* 88:2072-2081, 2000
11. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis. *Cancer Res*. 60:2562-2566, 2000

Appendices A-E

Concept Proposal Submission Form

This form has been set to accept 12 point Times New Roman font. For symbols use either (1) the Windows Character Map (under Accessories) or (2) from Word in a separate document, select Insert-Symbol...-(normal text). The use of other fonts is not recommended since the information may not be accurately transmitted.

By checking this box, I attest that I (1) have a masters or doctoral degree (e.g., M.S., M.A., Ph.D., D.Sc., D.N.S., M.D., D.O., etc.) from an accredited institution; (2) have access to the necessary space and equipment to perform the proposed studies; and (3) am employed by an eligible institution (i.e., for-profit and nonprofit organizations, public and private, such as universities, colleges, hospitals, laboratories, companies, and agencies of local, state, and federal governments, including military laboratories). Therefore, I am eligible to submit this proposal.

1. Proposal Title (160 character limit): Concurrent and independent genetic alterations in epithelial and stromal components of breast neoplasms: Implications for tumor development and progression

2. Principal Investigator (PI):

Last Name Tavassoli First Name Fattaneh MI A

3. Contact Information for PI:

Organization Name American Registry of Pathology

Department Name (if none, leave blank) Dept. of Gyn and Breast Pathology

Street Address Line 1 6825 16th Street, NW

Street Address Line 2 (if no line 2, leave blank) Building 54

City Washington State DC Country USA Zip Code 20306-6000

Phone 202-782-1600 Fax 202-782-3939

E-mail tavassol@afip.osd.mil

4. Administrative Representative Authorized to Conduct Negotiations:

Last Name King First Name Donald MI W

Concept Proposal Submission Form

5. Contact Information for Administrative Representative Authorized to Conduct Negotiations:

Organization Name American Registry of Pathology

Department Name (if none, leave blank)

Street Address Line 1 6825 16th Street, NW

Street Address Line 2 (if no line 2, leave blank) Building 54

City Washington State DC Country USA Zip Code 20306-6000

Phone 202-782-2102 Fax 202-782-4567

E-mail king@afip.osd.mil

6. Content Area of the Proposal

Please indicate up to two areas of emphasis to best describe your proposal. Enter the appropriate codes in the drop-down fields below.

- 01 Behavioral and Psychosocial Sciences
- 02 Cell Biology
- 03 Clinical and Experimental Therapeutics
- 04 Complementary and Alternative Medicine
- 05 Detection and Diagnosis
- 06 Endocrinology
- 07 Epidemiology
- 08 Genetics and Molecular Biology

- 09 Health Care Delivery
- 10 Immunology
- 11 Pathobiology
- 12 Primary Prevention
- 13 Radiation Sciences
- 14 Research Resources
- 15 Other, specify

Primary Proposal Content Area: 08

Secondary Proposal Content Area (Optional): 11

7. Will animals be used in the proposed work? No

8. Will human subjects be used in the proposed work? No

9. Will human anatomical substances, including primary and established cell lines, be used in the proposed work? Yes

10. Are laboratory experiments planned? Yes

11. PI gender (optional, select one): Female

12. PI ethnicity (optional, select one): White

If "Other" selected, specify _____

Data collected for questions 11 and 12 will be reported outside the Department of Defense only as grouped data without personal identifiers. Disclosure of this information is voluntary.

13. Budget Summary

Please adjust the indirect costs for your proposal below:

Direct Costs \$50,000.00

Indirect Costs \$4,000.00 (Please use the "Tab" key to go to the next field.)

Total Budget \$54,000.00

14. Proposal Body

In the space below, please provide a clear and concise overview of the proposed work in 5,500 characters or less (~1 page). As appropriate, include the hypothesis, supporting rationale, objectives, relevance to breast cancer, and a general plan for how the project will be executed. Figures are not permitted and the use of tables is discouraged. Proposals will be reviewed by diverse panels of scientists, clinicians, and consumer advocates; therefore, applicants should consider the varied backgrounds of the reviewers when preparing proposals.

A dynamic, reciprocal interaction between epithelial and mesenchymal (stromal) cells during embryogenesis is a well-recognized phenomenon, which determines the pattern and extent of the epithelial morphogenesis and cytodifferentiation. Recent studies have suggested that a similar interaction may also take place during tumor development or progression. The molecular mechanism for the epithelial-stromal interaction, however, remains to be identified. While a number of genetic alterations, including microsatellite instability, loss of heterozygosity (LOH), and gene amplification, have been observed in benign and malignant epithelial lesions, similar genetic alterations in the stromal component of these lesions have not been studied extensively. Using the PCR technique with 12 DNA markers, one of our previous studies simultaneously examined DNA extracts from microdissected epithelial cells and stromal cells near and far away from the epithelial component of breast specimens from 11 cancer patients and 10 normal controls (1). A high frequency of LOH at chromosomal loci that harbor tumor suppresser genes was detected in both stromal and cancerous epithelial cells. While LOH at several loci was detected exclusively in the stroma, 8 of 11 (73%) cancer cases showed at least one identical LOH in both epithelial and stromal cells. None of the normal controls displayed LOH. Our findings raise the provocative possibility that the elusive “pluripotent stem cells” in the breast may give rise to both malignant epithelial cells and the associated supportive stroma, and also suggest that genetic alterations in mammary stromal cells may precede genetic changes in epithelial cells. The manuscript of our results has been accepted and ranked as “highest priority” for publication in “Cancer Research” at the earliest possible date (1).

We propose to confirm our previous observations on a larger number of cases. More importantly, since it has been documented that the evolution and progression of human cancer involves a sequential, multistep process, starting from the transformation of normal cells to hyperplastic disorders, then to *in situ* lesions, and eventually to invasive and metastatic carcinomas, this study attempts to assess the correlation between epithelial and stromal cells during various steps of the hypothesized multistep process of carcinogenesis and tumor progression. The hypothesis to be tested is that the epithelial and stromal components of a majority of mammary carcinomas are derived through a clonal growth of a common progenitor; therefore, the epithelial cells and their surrounding stromal cells may share a common genetic

profile. The test will be accomplished by comparing the frequency and pattern of LOH, as well as the clonality between epithelial and stromal cells. The test will compare carcinomas and benign lesions characterized by a distinctive stromal alteration with carcinomas and benign lesions lacking a distinctive stromal change, to determine [1] whether the epithelial cells and their surrounding stromal cells display a similar frequency and pattern of LOH, and the same clonality; [2] whether the frequency and pattern of LOH correlates with the epithelial phenotype; [3] whether there is any shared LOH in various patterns of intraepithelial neoplasms and invasive carcinomas. The experimental procedures include: [1] Immunostaining sections with specific antibodies to highlight epithelial and stromal cells; [2] Microdissection of each epithelial phenotype and its surrounding stroma; [3] DNA extraction from microdissected samples; [4] PCR amplification of DNA extracts with fluorescent dye-labeled markers; [5] Electrophoresis of PCR products and detection of signals with an automated DNA sequencer. The protocol for each of the procedures (2-5), the tissue samples, and the facility to carry out the project are readily available in our department and the entire project can be accomplished within one year. The identification of genetic abnormalities in the stroma could facilitate the disclosure of the mechanism of tumor development and progression, and also may lead to development of novel therapeutic modalities that specifically target stromal cells, rather than the epithelial component of breast cancer.

15. References

No references are required for these submissions. Up to 5 references pertinent to the proposed study may be included in the boxes below. Limit each reference to 225 characters (~3 lines).

1.	Moinfar F, Man YG, Arnould L, Brathauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in stromal and epithelial cells of mammary carcinoma...Cancer Res (In press, May 1, 2000)
2.	Moinfar F, Man YG, Brathauer GL, Tavassoli FA. Loss of heterozygosity in mammary intraepithelial neoplasia---flat type (Clinging carcinoma in situ)---Asimilator of normal mammary epithelium. Cancer (In press, May 1, 2000)
3.	Mooney EE, Man YG, Brathauer GL, Tavassoli FA. Evidence that Leydig cells in Sertoli-Leydig cell tumors have a reactive rather than a neoplastic profile. Cancer 86:2312-2319, 1999
4.	Man YG, Moinfar F, Brathauer GL, Tavassoli FA. Five unique strategies for obtaining more valid gel images for LOH and clonality assessments with an automated DNA sequencer. Diagn Mol Pathol (In press)
5.	Man YG, Schammel DP, Tavassoli FA. Detection of telomerase activity in microdissected breast lesions. Cell Vision 5:84-85, 1998

Concept Proposal Submission Form

16. Principal Investigator Biographical Sketch

A biographical sketch of the PI must be submitted with the proposal but will not be considered in the peer or programmatic review process. A list of significant publications and a succinct summary of the investigator's professional experience in and/or potential for contribution to breast cancer research should be incorporated into the biographical sketch.

Biographical Sketch

Principal Investigator Name: Fattaneh A. Tavassoli

Position Title: Cairperson of Dept. of Gyn & Breast Path

EDUCATION/TRAINING: (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) Include the name of the institution and location, degree earned (if applicable), years attended, and field of study. Limit to 800 characters.

Southwest MO State College, Cum Laude,	BS, 1968,	Chemistry
Medical School of St. Louis University, St. Louis	MD, 1972,	Medicine

RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with your present position, list in chronological order previous employment, experience, and honors. Include present membership on any Federal Government public advisory committee. List in chronological order the titles, all authors, and complete references for all publications during the past 3 years and earlier publications pertinent to this application. If the list of publications in the last 3 years exceeds character limitations, select the most pertinent publications. Limit to 13,500 characters (~2.5 pages).

PROFESSIONAL EXPERIENCE

1972-1975 Resident, Dept of Surgical Pathology, Barnes Hopital, Washington U Medical School

1975-1976 Fellow, Dept of Gyn Pathology, St. John's Medical Center

1976-1992 Staff Pathologist and Vice Chairman, Gyn & Breast Pathology, AFIP

1992-1994 Chief, Gyn & Breast Pathology, Director of Research, Fairfax Hospital, VA

1995- Chairperson, Dept of Gyn & Breast Pathology, AFIP, ARP

Consultantship & Appointments

Clinical Assistant Professor of Pathology, Georgetown University Medical School, 1977

Lecturer and Instructor, Uniformed Services School of Health Sciences, 1976-1983, 1985-1991

Clinical Professor of Pathology, Uniformed Services School of Health Sciences, 1986-1992

Consultant to National Institutes of Health, Dept of Surgical Pathology, 1987-present

Editorial Boards:

1. Member of the editorial board, Human Pathology
2. Member of the editorial board, The Breast Journal
3. Member of the editorial board, The International J of Gyn Pathology
4. Member of the editorial board, The international J of Surg Pathol
5. Ad hoc reviewer, Pathology, Research, & Practice
6. Ad hoc reviewer, Cancer
7. Ad hoc reviewer, Women's Health
8. Ad hoc reviewer, J of National Cancer Institute

Professional Society, Offices:

1. Member of Council on Anat Pathology, American Society of Clinical Pathologists, 1989-present
2. Member at Large, International Society of Gyn Pathologists
3. Abstract Review Board, International Academy of Pathology, 1990-1992

Publications:

A: Book

FA Tavassoli. *Pathology of the Breast*. 2nd Edition, 1999, Appleton & Lange

B: Computer expert system

FA Tavassoli. *Pathology of the Breast. An interactive video expert system*. 1990, Intellipath, Santa Monica

C: Representative journal articles (1998-present)

1. Moinfar F, Man YG, Arnould , Brathauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. *Cancer Res* 60:2562-2566, 2000
2. Moinfar F, Man YG, Brathauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-Flat type ("Clining ductal carcinoma in situ"): A simulator of normal mammary epithelium. *Cancer* 88:2072-2081, 2000
3. Shen T, Vortmeyer AO, Zhuang Z, Tavassoli FA . High frequency of allelic loss of BRCA2 gene in pregnancy-associated breast carcinoma. *J Natl Cancer Inst.* 91:1686-1687, 1999
4. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis Meeting. *Oncogene* 19(8):968-988, 2000
5. Mooney EE, Vaidya KP, Tavassoli FA . Ossifying well-differentiated Sertoli-Leydig cell tumor of the ovary. *Ann Diagn Pathol* 4(1):34-38, 2000
6. Maitra A, Tavassoli FA, Albores-Saavedra J, Behrens C, Wistuba II, Bryant D, Weinberg AG, Rogers BB, Saboorian MH, Gazdar AF . Molecular abnormalities associated with secretory carcinomas of the breast. *Hum Pathol* 30(12):1435-1440, 1999
7. Devouassoux-Shisheboran M, Schammel MD, Man YG, Tavassoli FA. Fibromatosis of the breast: age-correlated morphofunctional features of 33 cases. *Arch Pathol Lab Med* 124(2):276-280, 2000
8. Devouassoux-Shisheboran M, Vortmeyer AO, Silver SA, Zhuang Z, Tavassoli FA. Teratomatous genotype detected in malignancies of a non-germ cell phenotype. *Lab Invest.* 80(1):81-86, 2000
9. Lininger RA, Zhuang Z, Man Y, Park WS, Emmert-Buck M, Tavassoli FA. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast. *Mod Pathol.* 12(12):1083-1089, 1999
10. Mooney EE, Man YG, Brathauer GL, Tavassoli FA . Evidence that Leydig cells in Sertoli-Leydig cell tumors have a reactive rather than a neoplastic profile. *Cancer* 86(11): 2312-2319, 1999
11. Ordi J, Schammel DP, Rasekh L, Tavassoli FA . Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases. *Mod Pathol.* 12(10):933-940, 1999

Concept Proposal Submission Form

12. Moinfar F, Man YG, Lininger RA, Bodian C, Tavassoli FA . Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type--benign and malignant intraductal proliferations. *Am J Surg Pathol* 23(9):1048-1058, 1999
13. Devouassoux-Shisheboran M, Silver SA, Tavassoli FA. Wolffian adnexal tumor, so-called female adnexal tumor of probable Wolffian origin (FATWO): immunohistochemical evidence in support of a Wolffian origin. *Hum Pathol* 30(7):856-863, 1999
14. Silver SA, Tavassoli FA. Osteosarcomatous differentiation in phyllodes tumors. *Am J Surg Pathol* 23(7):815-821, 1999
15. Mooney EE, Kayani N, Tavassoli FA. Spherulosis of the breast. A spectrum of mucinous and collagenous lesions. *Arch Pathol Lab Med.* 123(7):626-630, 1999
16. Mooney EE, Nogales FF, Tavassoli FA . Hepatocytic differentiation in retiform Sertoli-Leydig cell tumors: distinguishing a heterologous element from Leydig cells. *Hum Pathol.* 30(6):611-617, 1999
17. Devouassoux-Shisheboran M, Schammel DP, Tavassoli FA. Ovarian hepatoid yolk sac tumours: morphological, immunohistochemical and ultrastructural features. *Histopathology.* 34(5):462-469,1999
18. Mooney EE, Tavassoli FA. Papillary transitional cell carcinoma of the breast: a report of five cases with distinction from eccrine acrospiroma. *Mod Pathol* 12(3):287-294,1999
19. Gocht A, Bosmuller HC, Bassler R, Tavassoli FA, Moinfar F, Katenkamp D, Schirrmacher K, Luders P, Saeger W. Breast tumors with myofibroblastic differentiation: clinico-pathological observations in myofibroblastoma and myofibrosarcoma. *Pathol Res Pract* 195(1):1-10, 1999
20. Silver SA, Cheung AN, Tavassoli FA. Oncocytic metaplasia and carcinoma of the endometrium: an immunohistochemical and ultrastructural study. *Int J Gynecol Pathol.* 18(1):12-19,1999
21. Lininger RA, Fujii H, Man YG, Gabrielson E, Tavassoli FA . Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast. *Mod Pathol.* 11(12):1151-1159,1998
22. Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma--a preliminary report. *Cancer* 15;83(10):2139-2149,1998
23. Schammel DP, Mittal KR, Kaplan K, Deligdisch L, Tavassoli FA . Endometrial adenocarcinoma associated with intrauterine pregnancy. A report of five cases and a review of the literature. *Int J Gynecol Pathol* 17(4):327-335,1998
24. Koenig C, Tavassoli FA. Nodular hyperplasia, adenoma, and adenomyoma of Bartholin's gland. *Int J Gynecol Pathol* 17(4):289-294,1998
25. Lininger RA, Park WS, Man YG, Pham T, MacGrogan G, Zhuang Z, Tavassoli FA . LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. *Hum Pathol* 29(10):1113-1118,1998
26. Mannion C, Park WS, Man YG, Zhuang Z, Albores-Saavedra J, Tavassoli FA . Endocrine tumors of the cervix: morphologic assessment, expression of human papillomavirus, and evaluation for loss of heterozygosity on 1p,3p, 11q, and 17p. *Cancer.* 83(7): 1391-1400, 1998
27. Silver SA, Tavassoli FA . Primary osteogenic sarcoma of the breast: a clinicopathologic analysis of 50 cases. *Am J Surg Pathol* 22(8):925-933, 1998

ABSTRACTS ARE DUE JUNE 1, 2001.

Use Typewriter to Fill in the Blanks.

2001 OFFICIAL BREAST CANCER SYMPOSIUM ABSTRACT FORM

Type inside box below, using 11-point or larger Times or Times New Roman font.

Box is 5 inches wide by 6 inches high (12.7 x 15.24 cm). Stay inside borders.

Go to Page 3 for specific instructions.

1. PRESENTER NAME & ADDRESS:

Man Yan-Jao MS, PhD

Last Name First Name Middle Initial Degree

Circle Choice: Dr Prof. Mr. Mrs. Ms. Miss

AFIP, Gyn & Breast Pathology

Institution & Department

6825 16th Street, NW

Address

washington DC 20306-6000

City, State or Province, Postal/ZIP Code

USA

COUNTRY

202-782-1612

Telephone No. (including country & city codes)

202-782-3939

FAX No. (including country & city codes)

man@afip.osd.mil

E-Mail Address [Either FAX number OR E-mail is required.]

2. PRESENTATION PREFERENCE:

Poster Slide No preference
 I prefer to withdraw my abstract if my preference cannot be accommodated.

52 3. SUBJECT CATEGORY [Required]: Insert appropriate subject category number here. (See page 6.)

4. PERMISSION TO REPRODUCE PRESENTATION:

I have read Permission to Reproduce Presentation on page 2 and state as follows:

I agree to all recording and reproduction described.
 I decline all recording and reproduction described.
 I consent to the following ONLY:
 Audiotaping
 Videorecording
 Poster reproduction on paper and/or CD-ROM

5. ASTRAZENECA SCHOLARS PROGRAM (Trainees only):

Yes No

I am a scientist-in-training, or a physician-in-training. My application (form page 7) is enclosed with this abstract in order to be considered for the award.

6. THIS PORTION MUST BE COMPLETED AND SIGNED ON BEHALF OF ALL THE CO-AUTHORS:

PRESENTER DISCLOSURE DECLARATION (Required with EACH abstract): It is the policy of The University of Texas Health Science Center at San Antonio Medical School to insure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. The presenters must disclose any real or apparent conflict of interest that may have a direct bearing on the subject matter of the program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is merely to identify openly any potential conflict so that listeners may form their own judgments about the presentation with full disclosure of the facts.

I have a financial interest/arrangement or affiliation with one or more companies, named below, that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation. YES NO

If yes, list company names here:

Signature (REQUIRED)

Yan-Jao Man

Date

5/30/01

For Credit Card Payment: AMEX MasterCard Visa

Card Number _____ Exp. Date (MM/YY) _____ Cardholder Name _____

Amount \$ _____ for _____ abstracts @ \$35 each.

Signature _____

B



24th Annual San Antonio Breast Cancer Symposium

December 10-13, 2001

Sponsored by San Antonio Cancer Institute

August 1, 2001

ABSTRACT #24

Yan-Gao Man
AFIP
Gyn & Breast Pathology
6825 16th Street, NW
Washington, DC 20306-6000

General Session I: Monday 8:30 AM - 11:00 AM, Dec 10
General Session II: Monday 1:00 PM - 2:30 PM, Dec 10
General Session III: Tuesday 10:00 AM - 12 Noon, Dec 11
General Session IV: Wednesday 3:00 PM - 5:00 PM, Dec 12

RE: Primary bilateral breast cancers display different LOH and CGH profiles in both epithelial and stromal components.

Dear Dr. Man:

Your abstract referenced above has been accepted for slide presentation, General Session 3, at the 24th Annual San Antonio Breast Cancer Symposium. Instructions for a slide presentation are enclosed. Please follow them carefully.

Since yours is a General Session presentation, and two projectors are required for this very large meeting room, you must bring two sets of 35mm slides, and the sets must be identical. If you plan to do a computer presentation, notify Rich Markow by answering the questions in the lower right hand box of the Slide Presenter Instructions form and faxing it back to him as soon as possible.

If for any reason your presentation must be cancelled, notify the Symposium Coordinator as early as possible [E-mail Rmarkow@saci.org, FAX 210-949-5009, or phone 210-616-5912] before Friday, December 7. After that date, contact him at Marriott Rivercenter (210-223-1000). Be sure to mention your assigned abstract number. Failure to notify will result in activation of the No-Show Policy stated in the Abstract Submission Guidelines.

Don't forget to register to attend the meeting. You may register on line at www.sabcs.org. If you prefer fax or mail, a registration form is enclosed for your convenience. Pre-registration ends on October 31. **REGISTRATION IS CLOSED FROM NOVEMBER 1 UNTIL DECEMBER 9, 2001**. Your symposium materials will be given to you when you check in at SABCS in Conference Room 1-4.

For information on reserving a hotel room, go to the SABCS website at www.sabcs.org and click on the Housing button for instructions.

The final program booklet will be mailed in September. In the meantime, information is available on our website, which is updated periodically. Thank you for your abstract submission, and we look forward to your presentation.

Sincerely,
GARY C. CHAMNESS, PhD
Chairman, Abstract Selection Committee

Symposium Coordinator:
Lois E. Dunnington
(210) 616-5912
FAX (210) 949-5009

Cancer Therapy & Research Center (CTRC)
8122 Datapoint Drive, Suite 250
San Antonio, Texas 78229 USA

E-Mail Address:
Ldunning@saci.org
Symposium Website:
www.sabcs.org

24th Annual San Antonio Breast Cancer Symposium

Program Schedule

MONDAY DECEMBER 10, 2001

8:00-8:10 WELCOME

Opening Remarks

Charles A. Coltman, Jr., MD

8:10-8:30 The Role of Breast Cancer Advocates in Setting and Advancing a Research Agenda

Frances M. Visco

National Breast Cancer Coalition
Washington, DC

8:30-11:00 GENERAL SESSION I

- 8:30 1. A randomised placebo controlled trial to evaluate the effect of the bisphosphonate, clodronate, on the incidence of metastases and mortality in patients with primary operable breast cancer.
Powles TJ, Paterson AH, McCloskey E, Ashley S, Tidy VA, Kanis JA, Pykkänen L, Other Members of the International Multicentre Adjuvant Clodronate Group. Royal Marsden NHS Trust, London, United Kingdom; Tom Baker Cancer Centre and the University of Calgary, Calgary, Canada; University of Sheffield, Sheffield, United Kingdom; Leiras Clinical Research, Finland.
- 8:45 2. Acute myeloid leukemia and myelodysplastic syndrome following doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the NSABP experience.
Smith RE, Bryant J, DeCillis A, Anderson S. NSABP and Bristol-Myers Squibb.
- 9:00 3. Delivering full planned dose on time chemotherapy while lowering the incidence of febrile neutropenia hospitalizations: Initial results from a prospective study providing Filgrastim support to high risk breast cancer patients.
Rivera E, Erder HM, Fridman M, Brannan C, Frye DK, Hortobagyi GN. U.T. M.D. Anderson Cancer Center, Houston, TX; Amgen Inc., Thousand Oaks, CA; AMF Consulting Inc., Los Angeles, CA.
- 9:15 4. Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198).
Sledge GW, O'Neill A, Thor AD, Kahani SP, Zander PJ, Davidson NE. Eastern Cooperative Oncology Group.
- 9:30 5. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27.
NSABP, NSABP, Pittsburgh, PA.
- 9:45 6. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Lipton A, Ali S, Leitzel K, Demers L, Harvey H, Chaudri-Ross H, Brady C, Dugan M, Carney W. Hershey Medical Ctr, Hershey, PA; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp., East Hanover, NJ; Oncogene Science, Cambridge, MA.
- 10:00 7. The effect of tamoxifen on benign breast disease. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial.
Tan-Chiu E, Costantino J, Wang J, Paik S, Butch C, Wickerham DL, Wolmark N. NSABP Operations Office, Pittsburgh, PA.
- 10:15 8. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women.
Baum M, on behalf of the ATAC Trialists' Group.

10:30 9. Final survival analysis of the double-blind, randomized, multinational phase III trial of letrozole (Femara®) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer. Mouridsen H, Sun Y, Gershonovitch M, Perez-Carrion R, Smith R, Chaudri-Ross H, Lang R, Brady C, Dugan M. Rigshospitalet, Copenhagen, Denmark; Chinese Academy of Medical Sciences, Beijing, China; Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Hospital Universitario de la Princesa, Madrid, Spain; South Carolina Oncology Assoc., Columbia, SC; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp., E. Hanover, NJ.

10:45 10. Letrozole (Femara®) is a more effective anti-proliferative agent than tamoxifen irrespective of ErbB1 and/or ErbB2 positive status: evidence from a phase III randomized trial of neoadjuvant endocrine therapy for postmenopausal women with estrogen receptor positive primary breast cancer.

Ellis MJ, Jaenicke F, Llombart-Cussac A, Mauriac L, Miller WR, Evans DB, Brady C, Dugan M, Quebe-Fehling E, Borgs M. Duke University, Durham, NC; Universitaets Frauen-und Poliklinik, Hamburg, Germany; Instituto Valenciano de Oncologia, Valencia, Spain; Institut Bergonie, Bordeaux, France; West General Hospital, Edinburgh, United Kingdom; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp., E. Hanover, NJ; The Letrozole Neoadjuvant Breast Cancer Study Group.

11:00-12:00 WILLIAM L. MC GUIRE MEMORIAL LECTURE

Endocrine Therapy for Breast Cancer—Past and Future

Nancy E. Davidson, MD

Johns Hopkins University School of Medicine
Baltimore, Maryland

Supported by an educational grant from Glaxo SmithKline

12:00-1:00 LUNCH [Ticket Required]

1:00-2:30 GENERAL SESSION II

- 1:00 11. A common progenitor (adult stem) cell gives rise to both the glandular and myoepithelial cell lineages. A new cell biological concept as the basis of breast pathology.
Boecker W, Moll R, van Diest P, Dervan P, Buerger H, Brandt B, Holland R, Poremba C, Diallo R, Buchwallow I. Institute of Pathology, University of Muenster, Muenster, Germany; Center of Pathology, University of Marburg, Marburg, Germany; Institute of Pathology, Free University Hospital, Amsterdam, Germany; Institute of Pathology, University of Dublin, Dublin, Ireland; Institute of Clinical Chemistry and Laboratory Medicine, University of Muenster, Muenster, Germany; Institute of Pathology, University of Nijmegen, Nijmegen, Netherlands.
- 1:15 12. Risk of invasive local recurrence following therapy for ductal carcinoma in situ is a function primarily of time.
Skinner KA, Sparto R, Helsper JT, Baril N, Silberman H, Waisman J, Silverstein MJ. Surgery, Preventive Medicine, and Medicine, Norris Cancer Center, University of Southern California, Los Angeles, CA.
- 1:30 13. Endothelin-1 mediates pathological but not normal bone remodeling..
Mohammad KS, Yin JJ, Grubbs BG, Cui Y, Padley R, Guise TA. Medicine/Endocrinology, UTHSCSA, San Antonio, TX; Abbott Laboratories, Chicago, IL.
- 1:45 14. Prognosis following local recurrence after conservative surgery and radiation therapy for early-stage breast cancer.
Galper S, Blood E, Gelman R, Kohli A, Recht A, Harris J. Harvard Medical School, Boston, MA.
- 2:00 15. The learning curve in sentinel node biopsy in breast cancer: results from the ALMANAC trial.
Clarke D, Mansel RE, On behalf of ALMANAC trialists group. University Department of Surgery, Cardiff, Wales, United Kingdom.
- 2:15 16. A randomized trial comparing axillary dissection and axillary radiotherapy for early breast cancer: 15 year results.
Louis-Sylvestre C, Clough KB, Falou M-C, Salmon RJ, Fourquet A, Vilcoq JR. Surgery, Curie, Paris, France.

2:30-5:00	MINI-SYMPOSIUM I		DCIS Cost-Effectiveness	253-260 261-265
	What's New in Surgery for Breast Cancer?		Tumor Cell Biology	
	Anthony Lucci, MD, Co-Moderator Baylor College of Medicine, Houston, Texas And Monica Morrow, MD, Co-Moderator Northwestern University, Chicago, Illinois		Angiogenesis Antiestrogens DNA Repair Gene Therapy	266-271 272-274 275-277 278-280
2:30	Introduction	9:30-10:00	PLENARY LECTURE I	
2:30	Unresolved Issues in Sentinel Lymph Node Dissection for Breast Cancer		Antiangiogenesis Therapy—where are we now?	
	Anthony Lucci, MD Baylor College of Medicine Houston, Texas		Adrian L. Harris, MD, PhD University of Oxford Oxford, England, UK	
3:00	Ductal Lavage and Ductoscopy: The Opportunities and the Limitations	10:00-12:00	GENERAL SESSION III	
	Seema Khan, MD Northwestern University Chicago, Illinois		17. Utilization of gene expression profiling to identify markers of disease recurrence in node-negative breast cancer.	
3:30	Four or five day brachytherapy instead of six weeks of external beam radiotherapy in the treatment of breast cancer		Roche PC, Mertens ML, Couch FJ, Ingle JN, Leontovich AA, Perez EA, Lillie J. Mayo Clinic, Rochester, MN; Millennium Predictive Medicine, Cambridge, MA.	
	Robert Kuske, MD University of Wisconsin, Madison Madison, Wisconsin		18. Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization.	
4:00	Extending Breast Conservation		Mass R, Press M, Anderson S, Slamon D. Genentech, Inc., South San Francisco, CA; University of Southern California, Los Angeles, CA; Laboratory Corporation of America, Research, Triangle Park, NC; Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, CA.	
4:30	Ablation Techniques for Breast Cancer		19. Level-I evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N0 therapy trial.	
	Monica Morrow, MD Northwestern University Chicago, Illinois <i>Supported by an educational grant from AstraZeneca Pharmaceuticals</i>		Harbeck N, Meisner C, Prechtel A, Untch M, Selbmann H-K, Sweep F, Graeff H, Schmitt M, Jaenicke F, Thomssen C, for the Chemo N0 Study Group. Frauenklinik, Technische Universitaet Muenchen, Munich, Germany; Institut fuer Medizinische Informationsverarbeitung, Universitaet Tuebingen, Tuebingen, Germany; Frauenklinik Grosshadern, Ludwig-Maximilians-Universitaet, Munich, Germany; Universitaetfrauenklinik Eppendorf, Hamburg, Germany; Dept. of Chemical Endocrinology, University Medical Center Sint Radboud, Nijmegen, Netherlands.	
5:00-7:00	POSTER SESSION I & RECEPTION (#101-180)		20. Telomerase is a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR expression.	
	Detection / Diagnosis		Poremba C, Diallo R, Heine B, Sauter G, Boecker W. Gerhard-Domagk-Institute of Pathology, Westfaelische Wilhelms-University, Muenster, Germany; Institute of Pathology, Free University, Berlin, Germany; Institute of Pathology, University of Basel, Basel, Switzerland.	
	Axillary/Sentinel Nodes 101-118		21. Persistence of occult metastatic cells in bone marrow of breast cancer patients despite systemic adjuvant treatment.	
	Biopsy Techniques 119-124		Janni WJ, Strobl B, Schindlbeck C, Rjosk D, Kentenich C, Stephan B, Harald S. I. Frauenklinik, LMU, Munich, Germany; Frauenklinik, TU, Munich, Germany.	
	Risk and Prevention	10:45	22. Persistence of solitary breast cancer cells in the secondary site: a possible source of tumor dormancy.	
	Diet and Nutrition 125		Naumov GN, Kerkvliet N, Wilson SM, Nadkarni K, Morris VL, MacDonald IC, Groom AC, Chambers AF. University of Western Ontario, London, ON, Canada; London Regional Cancer Centre, London, ON, Canada.	
	Familial Breast Cancer 126-130			
	Prevention 131-139			
	Treatment	11:00	23. Genetic alterations in the progression of non-invasive to invasive breast cancer.	
	Breast Conservation 140-151		Li Z, Tsimelzon A, Immaneni A, Mohsin SK, Hilsenbeck SG, Clark GC, Fuqua SA, Osborne CK, O'Connell P, Allred DC. Breast Center, Baylor College of Medicine, Houston, TX.	
	Radiation Therapy 152-159			
	Surgery 160-163			
	Tumor Cell Biology	11:15	24. Primary bilateral breast cancers display different LOH and CGH profiles in both epithelial and stromal components.	
	Molecular Biology 164-167		Man YG, Moiñfar F, Shekitka KM, Stamatasos M, Lininger RA, Kuhls E, Brathauer GL, Tavassoli FA. Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC.	
	Growth Factors/Inhibitors 168-174			
	Oncogenes/Tumor Suppressor Genes 175-180			
7:30-9:30	POSTER SESSION II & CONTINENTAL BREAKFAST (#201-280)	11:30		
	Detection / Diagnosis			
	Mammography/Imaging 201-213			
	Screening 214-219			
	Prognosis and Response Predictions	11:45		
	Predictive Factors 220-240			
	Risk and Prevention			
	Risk Factors 241-242			
	Adjuvant Therapy 243-252			

12:00-12:55	LUNCH [Ticket Required]		Chemotherapy-General Chemotherapy – Support	352-365 366
1:00-2:00	CASE PROBLEMS IN PRIMARY BREAST CANCER		Tumor Cell Biology	367-373
2:00-5:00	MINI-SYMPHOSIUM II Translational Discoveries from the SPOREs Suzanne AW Fuqua, PhD, Moderator Baylor College of Medicine, Houston, Texas		Cell Biology Drug Resistance	374-380
2:00	Introduction	9:30-12:00	MINI-SYMPHOSIUM III	
2:05	A Hypersensitive Mutant Estrogen Receptor Alpha is Present in Most Invasive Breast Cancers Suzanne AW Fuqua, PhD Baylor College of Medicine Houston, Texas	9:30	Breast Imaging: Present and Future Richard Elledge, MD, Moderator Baylor College of Medicine Houston, Texas	
2:30	Strategies to Decipher SERM Stimulated Breast and Endometrial Cancer Growth V. Craig Jordan, PhD Northwestern University Chicago, Illinois	9:30	Introduction Seeing is Believing: Visualizing Gene Expression and Secondary Messengers by MRI Thomas J. Meade, PhD California Institute of Technology Pasadena, California	
2:55	Expression of Novel Transforming Oncogene GKL/F/KLF4 in Breast Cancer J. Michael Ruppert, MD, PhD University of Alabama at Birmingham Birmingham, Alabama	10:00	Magnetic Resonance Elastography Don Plewes, MD Sunnybrook Health Science Center & Women's College Toronto, Ontario, Canada	
3:20	Roles of G1 Cyclins in Mammary Tumorigenesis Yan Geng, PhD Dana-Farber Cancer Institute Boston, Massachusetts	10:30	Breast Cancer Detection Using Functional Optical Spectroscopy and Imaging Bruce J. Tromberg, MD University of California, Irvine Irvine, California	
3:45	Pleiotropin and its Receptor in Breast Cancer Anton Wellstein, PhD Georgetown University Medical Center Washington, DC	11:00	Positron Emission Tomography: Current and Future Applications Richard Wahl, MD Johns Hopkins University School of Medicine Baltimore, Maryland	
4:10	Anti-HER2 Immunoliposomes for Targeted Drug Delivery John W. Park, MD University of California, San Francisco San Francisco, California	11:30	Using Magnetic Resonance Spectroscopy to Diagnose and Predict Therapeutic Response in Breast Cancer Michael Garwood, PhD University of Minnesota Minneapolis, Minnesota	
4:35	Application of Methylated Gene Markers to the Early Detection of Breast Cancer in Ductal Lavage Fluid Saraswati Sukumar, PhD Johns Hopkins University School of Medicine Baltimore, Maryland	12:00-12:55	LUNCH [Ticket Required]	
5:00-6:30	OPEN	1:00-2:00	CASE PROBLEMS IN ADVANCED BREAST CANCER	
6:30-8:30	THE BRINKER INTERNATIONAL AWARDS DINNER The Susan G. Komen Breast Cancer Foundation and the 24th Annual San Antonio Breast Cancer Symposium cordially invite you to join us in the Marriott Rivercenter ballroom for dinner and presentation of the Brinker International Awards for Breast Cancer Research. [Ticket Required]	2:00-2:30	PLENARY LECTURE II Post surgery radiation therapy for breast cancer: A review and critique of the overview analysis Allen Lichter, MD University of Michigan Ann Arbor, Michigan	
7:30-9:30	POSTER SESSION III & CONTINENTAL BREAKFAST (#301-380) Detection/Diagnosis Circulating Markers 301-304 Marrow and Blood Micrometastases 305-309 Prognosis and Response Predictions Prognostic Factors 310-341 Prognostic Factors – Methods 342-345 Outreach Advocacy/Education 346-351 Treatment	2:30-3:00	PLENARY LECTURE III Predisposition to breast cancer : low penetrance genes - how and why Prof. Bruce Ponder Cambridge Institute for Medical Research Cambridge, England, UK	
		3:00-5:00	GENERAL SESSION IV 25. A hypersensitive estrogen receptor α is common in invasive breast cancer. Hopp TA, Van M, O'Connell P, Hilsenbeck SG, Mohsin S, Allred DC, Fuqua SA. Breast Center, Baylor College of Medicine, Houston, TX.	
		3:15	26. Use of hormonal contraceptives and breast cancer risk: "The Women's Lifestyle and Health Study". Kumle M, Weiderpass E, Braaten T, Adami H-O, Lund E. Institute of Community Medicine, University of Tromsoe, Tromsoe, Norway; Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden; International Agency for Research on Cancer, Lyon, France.	

3:30	27. Epirubicin/Docetaxel (ET) versus 5FU/Epirubicin/Cyclophosphamide (FEC) combinations as first line chemotherapy in patients with metastatic breast cancer. Bonneterre JM, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre M-EA, Bendahmane B. Breast Cancer, Centre O. Lambret, Lille, France; Medical Oncology, Institut Curie, Paris, France; Medical Oncology, Centre R. Huguenin, Saint-Cloud, France; Radiation Therapy, CHU Bretonneau, Tours, France; Clinical Research Unit, Centre O. Lambret, Lille, France; Aventis, Paris, France.	Detection/Diagnosis Detection 501-505
3:45	28. Circulating extracellular domain of HER2 can be correlated with clinical response to chemotherapy in locally advanced breast cancer. Stearns V, Yamauchi H, Singh B, Slack R, Hayes DF. Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC.	Treatment Neoadjuvant Chemotherapy 506-519 Antibody Therapy 520-530 Other Therapies 531-535 Patient Management 536-540 Psychosocial Aspects 541-544 Male Breast Cancer 545
4:00	29. Inhibition of VEGF/KDR signaling by TSU-68 (SU6668), an oral anti-angiogenic agent, can synergistically enhance the anti-tumor activity of taxol; a new paradigm for breast cancer chemotherapy. Yonekura K, Basaki Y, Fujita H, Chikahisa L, Hashimoto A, Cherrington J, Shawver L, Yamada Y, Kitazata K. Cancer Research Laboratory, Taiho Pharmaceutical Co., Ltd., Hannno, Saitama, Japan; Sugen, San Francisco, CA.	Tumor Cell Biology Apoptosis 546-550 Endocrinology 551-555 Immunology/Immunotherapy 556-562 Metastasis/Invasion 563-580
4:15	30. Therapeutic and chemopreventive effects of R115777, a farnesyl transferase inhibitor, on methylnitrosourea (MNU)-induced rat mammary cancer. Lubet RA, You M, Ruchon Y, End D, Wouters W, Christov K, Grubbs CJ. NCI, DCP, Ohio State Univ., Janssen Research Foundation, Univ. Ill. at Chicago, Univ. of Alabama at Birmingham.	9:30-10:00 PLENARY LECTURE IV Lobular carcinoma in situ: Much ado about nothing Prof. Sunil R. Lakhani Institute of Cancer Research London, England, UK
4:30	31. Dissection of cooperating genetic pathways involved in aggressive early onset breast cancer reveals mutually distinct roles for BRCA1 and HER2/neu genes. Olopade Ol, Grushko TA, Hagos F, Adeyanju M, Adams AJ, Blackwood-Chirchir AM, Weber BL, Perou CM. Department of Medicine, University of Chicago, Chicago, IL; Department of Medicine, University of Pennsylvania, Pennsylvania, PA; Department of Genetics, University of North Carolina, Chapel Hill, NC.	10:00-12:30 MINI-SYMPORIUM IV Metastasis in Breast Cancer: Targets for Diagnosis and Treatment Gregory R. Mundy, MD, Moderator University of Texas Health Science Center San Antonio, Texas
4:45	32. Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinoma. Wilton CJ, Reeves JR, Going JG, Cooke TG, Bartlett JM. University Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom; University Department of Pathology, Glasgow Royal Infirmary, Glasgow, United Kingdom.	10:00 Introduction 10:00 The Role of TGFβ in Breast Cancer Metastasis Theresa A. Guise, MD University of Texas Health Science Center San Antonio, Texas
5:00-7:00	POSTER SESSION IV & RECEPTION (#401-480) Detection/Diagnosis Diagnostic Pathology 401-410 Epidemiology Epidemiology 411-418 Racial Aspects 419-421 Treatment Chemotherapy – High Dose 422-425 Chemotherapy – New Drugs and Formulations 426-442 Endocrine Therapy 443-459 Hormone Replacement Therapy 460-462 Tumor Cell Biology Steroid Receptors 463-472 Antigens and Markers 473-475 Genetics 476 Tumor Biology 477-480 <i>Supported by an educational grant from Pharmacia Oncology</i>	10:30 Cellular and Molecular Mechanism of Bone Cancer Pain Denis Clohisy, MD University of Minnesota Minneapolis, Minnesota 11:00 Bisphosphonates and Tumor Progression in Osteotropic Breast Cancer Gabriel van der Pluijm, PhD Leiden University Medical Center Leiden, The Netherlands 11:30 Angiogenesis and the Regulation of the Different Patterns of Metastatic Disease Michael S. O'Reilly, MD MD Anderson Cancer Center Houston, Texas 12:00 The Role of IGF/NF-κB in Breast Cancer Metastasis to Bone Toshiyuki Yoneda, DDS, PhD University of Texas Health Science Center San Antonio, Texas <i>Supported by an educational grant from Aventis Oncology</i>
		12:30 ADJOURNMENT, 24th Annual San Antonio Breast Cancer Symposium
7:30-9:30	POSTER SESSION V & CONTINENTAL BREAKFAST (#501-580)	1:00-4:30 SATELLITE SYMPOSIUM Optimal Therapy for Primary and Metastatic Breast Cancer: Emerging Standards and New Approaches Jointly sponsored by Seton Hall University and The American Academy of Continuing Medical Education For information, contact: Sondra Moylan Phone 609-921-6622 FAX 609-921-6428 Email: smoylan@academycme.org <i>Supported by an educational grant from Pharmacia Oncology</i>

THURSDAY DECEMBER 13

7:30-9:30 POSTER SESSION V & CONTINENTAL BREAKFAST (#501-580)

ABSTRACT FORM FOR PAPER SUBMISSIONS

United States and Canadian Academy of Pathology

Name and Address of person to be notified of acceptance or rejection of abstract:

Yan-gao Man, M.D., Ph.D.

Dept. of Gyn & Breast Pathology
Armed Forces Institute of Pathology
6825 16th Street, NW
Washington DC 20306-6000

Phone #:

202-782-1612

★ To be notified that your abstract has been received for processing enter below either a
 FAX # or an Email Address

202-782-3939

ABSTRACT FEE OF \$ 20 must accompany each abstract

A check payable to USCAP Abstracts is enclosed.

Please charge to: Master Card VISA Am Ex Exp. Date _____

Card #: _____

Signature: _____

ABSTRACT BOX - Use 8 point type - Times New Roman is recommended.

Morphologically comparable stromal cells associated with benign and malignant mammary epithelial lesions show different immunohisto-chemical and genetic profiles

YG Man, KM Shekitka, M Stamatakos, L Tai, GL Brathauer, PY Chen, FA Tavassoli
Dept. of Gynecological and Breast Pathology, The Armed Forces Institute of Pathology and American Registry of Pathology, 6825 16th Street, NW, Washington, DC 20306

Background: Our previous studies on paraffin embedded tissues from patients with mammary and cervical carcinomas revealed high frequencies of independent and concurrent loss of heterozygosity (LOH) in microdissected epithelial (EP) tumor cells and adjacent or distant stromal (ST) cells.

Design: To confirm previous findings on a larger scale and wider spectrum, and to determine whether morphologically comparable ST cells associated with benign and malignant EP tumors are bio-functionally and genetically different, the current study compared the immunostaining patterns and the frequency of LOH in EP and ST cells microdissected from infiltrating syringomatous adenomas and tubular carcinomas.

Results: Although the ST components in these two lesions were morphologically comparable, they displayed a substantially different immunostaining pattern to several antibodies, including antibodies to cell proliferation associated proteins, blood vessel components, and extracellular matrix molecules. The ST cells from these two lesions also displayed a substantially different frequency and pattern of LOH at multiple chromosomal loci, including 3p, 11p, 13p, and 13q. The ST cells from both lesions, however, displayed no distinct LOH or micro-satellite instability with multiple DNA markers at chromosome 17p.

Conclusions: These findings suggest that morphologically comparable ST cells associated with benign and malignant EP lesions are bio-functionally and genetically different, closely correlated with those in their EP counterparts. These findings also suggest that the bio-functions of ST cells in both lesions might not be directly subjected to the regulation of the p53 gene.

Acknowledgement: This study is supported by Congressionally Directed Medical Research Programs, The New Concept Award (DAMD17-00-1-0676) to Dr. Fattaneh A. Tavassoli and The Career Development Award (BC001187) to Dr. Yan-gao Man.

Items Below Must be Completed:

Enter

Category # 3
(see the list in the instructions)

Presentation Choice:

Poster Only _____

Either Poster or Platform ✓

Stowell-Orbison or
Autopsy Award(s) N/A
(application form enclosed or you
will not be in the competition)

Disclosure Form Enclosed ✓
(or abstract will not be accepted
for review)

Fax # or Email at left ✓
(or you will not be notified
that your abstract was received)

Recommended format used ✓

8 point or larger type used ✓
(or your abstract will be illegible
in all USCAP publications)

DEADLINES:

Mailed Paper Submissions
must be RECEIVED
(not postmarked)
by September 17, 2001

Mail to:
USCAP Abstracts
C/o Marathon Multimedia
1201 West Division Street
Faribault, MN 55021

Additional Information:

<http://www.uscap.org>

Telephone: (706) 733-7550

Electronic Submissions
must be received by:
11:59 c.d.t. September 24, 2001



*This form may be photocopied *

C

ABSTRACT FORM FOR PAPER SUBMISSIONS

United States and Canadian Academy of Pathology

Name and Address of person to be notified of acceptance or rejection of abstract:

Yan-gao Man, M.D., Ph.D.
Dept. of Gyn & Breast Pathology
Armed Forces Institute of Pathology
6825 16th Street, NW
Washington DC 20306-6000
Phone #: 202-782-1612

★ To be notified that your abstract has been received for processing enter below either a
 FAX # or an Email Address

202-782-3939

Items Below Must be Completed:

Enter 3

Category # 3
(see the list in the instructions)

Presentation Choice:

Poster Only _____

Either Poster or Platform ✓

Stowell-Orbison or
Autopsy Award(s) N/A
(application form enclosed or you
will not be in the competition)

Disclosure Form Enclosed ✓
(or abstract will not be accepted
for review)

Fax # or Email at left ✓
(or you will not be notified
that your abstract was received)

Recommended format used ✓

8 point or larger type used ✓
(or your abstract will be illegible
in all USCAP publications)

ABSTRACT FEE OF \$ 20 must accompany each abstract

A check payable to *USCAP Abstracts* is enclosed.

Please charge to: Master Card VISA Am Ex Exp. Date _____

Card # _____

Signature: _____

ABSTRACT BOX - Use 8 point type - Times New Roman is recommended.

Focal loss of estrogen receptor (ER) expression in ER positive ductal intraepithelial neoplasia is associated with disruptions of the immediate subjacent myoepithelial cell layer

YG Man, KM Shekitka, JS Saenger, L Tai, GL Brathauer, PY Chen, FA Tavassoli
Department of Gynecological and Breast Pathology, The Armed Forces Institute of Pathology and American Registry of Pathology, 6825 16th Street, NW, Washington, DC 20306

Background: Our previous study using double immunostaining with antibodies to ER and smooth muscle actin (SMA) revealed patchy disruptions in the myoepithelial (ME) cell layer immediately subjacent to ER negative epithelial (EP) cells in mammary ducts with ostensibly EP proliferation.

Design: To confirm this finding on a larger scale, the same protocol was used to assess the association between ER expression and disruptions of ME cell layers on paraffin tissue sections from 125 patients with various grades of ductal intraepithelial neoplasia. The disruption of ME cell layers is defined as widening of a ME cell layer gap equal to the diameter of at least 3 EP cells in the cross section of a given duct. Focal loss of ER expression is defined as a significant reduction or complete loss of ER expression in a cluster of EP cells immediately overlying the disrupted ME cell layer, compared to strong ER expression in the remaining neoplastic cells within the same duct. The total number of the cross sections of ducts with proliferative changes was counted. All profiles with disrupted ME cell layers were photographed, and prints were made at a magnification of 400-800X for immunohistochemical and morphological assessments.

Results: Of the 125 cases, 62 (49.6%) showed disrupted ME cell layers; 246 (6.6%) disruptions were detected from 3,733 evaluated duct cross sections. Of the 62 cases with disrupted ME cell layers, 40 (64.5%) contained less than 4 and 22 (35.5%) displayed more than 4 disruptions. Of these disruptions, 225 (91.5%) from 59 cases were associated with focal loss of ER expression and 21 (8.5%) from 9 cases were subjacent to ER positive cells. The frequency and pattern of disruptions was generally independent of the size of ducts or the degree of neoplasia. The cells overlying the ME disruptions were generally morphologically indistinguishable from adjacent neoplastic cells within the same duct on routine H&E sections.

Conclusions: These findings suggest that focal loss of ER expression might play an important role in tumor progression and that double immunostaining with SMA and ER could assist in detection of incipient cancer invasion.

Acknowledgement: This study is supported by Congressionally Directed Medical Research Programs, The Idea Award (BC001187) and Career Development Award (BC001186) to Yan-gao Man, MD., Ph.D..

DEADLINES:

Mailed Paper Submissions
must be RECEIVED
(not postmarked)
by September 17, 2001

Mail to:
USCAP Abstracts
C/o Marathon Multimedia
1201 West Division Street
Faribault, MN 55021

Additional Information:

<http://www.uscap.org>

Telephone: (706) 733-7550

Electronic Submissions
must be received by:
11:59 c.d.t. September 24, 2001



Yan-Gao Man
 Elizabeth A. Kuhls
 Gary L. Brathauer
 Farid Moinfar
 Fatteneh A. Tavassoli

Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology (AFIP) and American Registry of Pathology (ARP), Washington, DC, USA

Multiple use of slab gels in sequencing apparatus for separation of polymerase chain reaction products

Attempting to assess whether a decrease of the electrophoresis temperature could prevent or reduce the extent of gel well deformations, and whether the utilization of native polyacrylamide gels (without urea) could speed up the separation of polymerase chain reaction (PCR)-amplified products with an automated 377 DNA sequencer, denatured PCR products were subjected to electrophoresis in 6% native gels under 45°C. Results show that a decrease of the electrophoresis temperature from 51°C (recommended by the User's Manual) to 45°C substantially facilitates the preservation of gel wells, and that all PCR products tested migrate significantly faster in native than in denatured (with urea) gels of the same concentration. The combination of a 6% native gel and a lower (45°C) electrophoresis temperature permits multiple uses of a given gel with consistent results, consequently reducing the electrophoresis time and reagent costs.

Keywords: Electrophoresis / Native polyacrylamide gels / Polymerase chain reaction products / Automated DNA sequencer

EL 4449

Nucleic acids

Attempting to reduce the electrophoresis time and reagent costs for evaluating polymerase chain reaction (PCR) amplified products, our recent study [1] assessed the mixture of multiple PCR products in the same well in a single run, with an automated 377 DNA sequencer and corresponding software (Perkin-Elmer, Foster City, CA, USA). Four PCR products with different molecular masses, ranging from 106 to 290 base pairs (bp), were pooled, the mixture and each of the corresponding pooled samples were separately loaded into 5–6% denatured polyacrylamide gels, and subjected to electrophoresis at 50°C according to the manufacturer's instructions [1]. Although the specific PCR product from each of four pooled samples was distinct, similar to those of corresponding samples that were individually loaded, the wells of gels were often deformed after electrophoresis, making repeated usage of the gel undesirable. This study attempted to determine whether a decrease of the electrophoresis temperature could prevent or reduce the extent of gel deformations, consequently allowing a given gel to be used multiple times. In addition, as a previous study [2] showed that the application of native gels facilitated the sizing of large DNA fragments (\approx 2,500 bp), this study attempted to determine whether the application of

native gels could benefit the separation of smaller DNA molecules (<300 bp) of PCR-amplified products. Ultimately, this study attempted to determine whether the combination of a native gel and a decreased electrophoresis temperature could permit multiple uses of a gel and a further reduction of the electrophoresis time and reagent costs.

An automated 377 DNA sequencer with the corresponding software, the User's Manual, the DNA size standard (GENESCAN-500), and the gel loading buffer (10X Blue Dextran/EDTA) were obtained from Perkin-Elmer. PCR-amplified products with fluorescent dye labeling were obtained from our previous studies [1, 3–6]. Polyacrylamide gel solution (40% acryl/bis 19:1) and urea were purchased from Bio-Rad (Hercules, CA, USA). TEMED, formamide, and ammonium persulfate were bought from Amresco (Solon, OH, USA). Denatured gels (with urea) were prepared strictly following the formula provided by the User's Manual, and native gels at the same concentrations were prepared using the same formula but without urea. For a direct comparison, denatured and native gels at the same concentration were prepared in the same plate. This was accomplished by adding two additional spacer bars to the center of the gel plate to create two isolated compartments, which allow two different gel formulations to be poured simultaneously into the same plate apparatus.

Samples were prepared for electrophoresis, according to the User's Manual and our previously published protocol [1]. Briefly, each PCR product or a mixture of 3–4 PCR products was mixed with the loading buffer containing

Correspondence: Yan-gao Man, MD, PhD, Department of Gynecologic & Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, 6825 16th Street, N.W., Washington, DC 20306-6000, USA

E-mail: man@afip.osd.mil
Fax: +202-782-3939

formamide. The mixtures were incubated for 4 min at 95°C, and then placed in ice for loading. To assess the impact of a decreased electrophoresis temperature on the preservation of the gel wells, different gels of the same concentration and formulation were subjected to electrophoresis under the temperature recommended by the User's Manual (51°C) and a decreased temperature (45°C). After each electrophoresis, 100–150 µL of the loading buffer were added to the slot to elucidate the wells. The averaged number of nondeformed wells in 3–4 separated runs under each temperature was compared. To evaluate the potential benefits of a native gel over a denatured gel of the same concentration, the identical PCR mixtures were subjected to electrophoresis in each gel type. The averaged relative mobilities of the identical PCR products and the separation time in 3–4 separated runs of each gel type were statistically compared with the Student's *t*-test. To determine whether a combination of a native gel and a decreased temperature may permit multiple uses of a gel and a reduction of the electrophoresis time, a 6% native gel was subjected to electrophoresis multiple times under 45°C for the identical PCR mixtures. The relative mobility and separation time of the identical PCR products on gels used multiple times were statistically compared to those in gels used only once, and also to those in gels under the conditions recommended by the User's Manual. In 4% denatured and native gels, only 26 and 38% of the wells were not deformed under 51°C and 45°C, respectively. In 6% denatured and native gels, however, 44 and 94% of the wells remained unimpaired under 51 and 45°C, respectively, suggesting that a decreased electrophoresis temperature facilitates the preservation of the wells of 6% gels.

The averaged separation time in denatured and native gels at both 51°C and 45°C were listed in Table 1. The separation time for each of the PCR products assessed at both 51°C and 45°C was significantly shorter ($p < 0.01$) in both 4 and 6% native gels than in the corresponding denatured gels. Figures 1a and b show the band pattern image of three PCR products sized from 100 to 217 bp in 6% denatured and native gels on the same plate under the same electrophoresis temperature. Each of the three PCR products and the DNA size standard appeared to migrate substantially faster in the native gel than in the denatured gel. This was confirmed by the statistical comparison of the relative mobilities, which revealed that the migration of all three PCR products was indeed significantly faster ($p < 0.01$) in the native than in the denatured gel (Table 2). One conceivable drawback of native gels is the proximity of the bands which, while still sharply defined, are confined to a more limited expanse of the gel. This drawback, however, has little impact on the interpretation of the results, as the band pattern image can be

Table 1. Comparison of the averaged separation time between denatured and native gels at 51°C and 45°C

Gel type	Separation time (min) for PCR products of different sizes (bp)		
	100–112	142–158	210–227
4% Denatured at 51°C	37	44	57
4% Native at 51°C	25	30	35
4% Denatured at 45°C	39	48	63
4% Native at 45°C	30	34	41
<i>p</i>	<0.01	<0.01	<0.01
6% Denatured at 51°C	53	68	91
6% Native at 51°C	34	44	56
6% Denatured at 45°C	59	75	101
6% Native at 45°C	37	45	58
<i>P</i>	<0.01	<0.01	<0.01

Identical PCR mixtures were subjected to electrophoresis in each gel type at 51°C and 45°C. The averaged separation time in 3–4 separated runs of each gel type at each temperature was statistically compared with the Student's *t*-test.

Table 2. Comparison of relative mobilities of PCR products on 6% denatured and native gels on the same plate under the same electrophoresis condition

Gel type	Relative mobilities of PCR products with different sizes (bp)		
	100–112	142–158	210–227
6% Denatured	0.60–0.57	0.43–0.40	0.18–0.15
6% Native	0.82–0.80	0.74–0.73	0.63–0.61
<i>P</i>	<0.01	<0.01	<0.01

Two isolated compartments were created on the same gel plate by adding two additional space bars to the center of the plate, and 6% denatured and native gels were simultaneously poured into each compartment. Three identical PCR products and a DNA standard were subjected to electrophoresis in each gel under the same condition. The relative mobilities of the same PCR products were statistically compared with the Student's *t*-test.

transformed into a densitometric graph, which is more objective and easier to interpret (while far more time-consuming). As shown in Fig. 1c and 1d, each of the two alleles of the PCR product is clearly elucidated as a distinct curve in both native and denatured gels, indicating that the same PCR product can be separated in both gels.

The combination of a 6% native gel and a decreased electrophoresis temperature permitted multiple uses of a given gel, consequently reducing the electrophoresis time




Figure 1. Separation of PCR products on 6% denatured and native gels on the same plate under the same electrophoresis condition. Two isolated compartments were created on the same gel plate by adding two additional space bars to the center of the plate, and 6% denatured and native gels were simultaneously poured into each compartment. Three identical PCR products and a DNA standard were subjected to electrophoresis in each gel under the same condition. Band pattern and densitometric gel images were prepared based on the User's Manual and our published protocol. The specific PCR products were underlined. The numbers on the left of each figure represent the time/molecular weight scale. The red bands represent the DNA size standard, containing 16 ROX-labeled DNA fragments, ranging from 35 to 500 base pairs. (a) The band pattern image on the denatured gel. (b) The band pattern image on the native gel. (c) The densitometric image on the denatured gel. (d) The densitometric image on the native gel.

and reagent costs. In most cases, a given 6% native gel could be continuously used 3–4 times under 45°C. Although slightly deformed wells were occasionally observed after each run, they could usually be fixed with the gel cleaning apparatus designed in our laboratory [1]. Table 3 shows the comparison of the averaged separation time of three PCR products in 3–4 separate sets of electrophoresis in a 6% native gel that was used four times. The averaged separation times among four different runs were almost identical.

Table 4 shows the comparison of the corresponding relative mobilities. Again, the mobilities of all the PCR products among different runs were not statistically different ($p > 0.05$). Figures 2a–e show the band pattern images of four sequential runs of the identical PCR mixtures in the same gel, and of the first run in a gel that was prepared and subjected to electrophoresis strictly based on the User's Manual. The shape and intensity of DNA bands among four sequential runs were very similar to each other, and also similar to those in the comparing gel,




Figure 2. Comparison of the gel images on gels used different times. Three identical PCR products and a DNA size standard were subjected to electrophoresis in a 6% native gel four times at 45°C and in a 4% denatured gel once at 51°C. Band pattern and densitometric gel images were prepared based on the User's Manual and our published protocol. The specific PCR products were underlined. The numbers on the left of each figure represent the time/molecular weight scale. The red bands represent the DNA size standard containing 16 ROX-labeled DNA fragments, ranging from 35 to 500 bp. (a)–(d) The band pattern images on the gel during the first to fourth runs. Note the persisted large DNA fragments from the previous run (arrows). (e) The band pattern image on a 4% denatured gel at the first run at 51°C. (f)–(g) The densitometric images on the gel at the first and fourth run. (h) The densitometric image on the 4% denatured gel at the first run.

which was conformed by the raw data collected by the detection system during the electrophoresis process (data not shown). Figures 2f–h show the densitometric graphs of the first and the fourth run in the same gel, and of the first run in the comparing gel. Again, the height of the peak and the curve pattern in the fourth run was similar to those in the first run of both the same gel and the comparing gel.

In summary, this study has demonstrated that a decrease of electrophoresis temperature from 51 to 45°C facilitates the preservation of gel wells. This study has also shown that native gels could serve as a rapid tool for a preliminary run that would quickly show the outcome of PCR amplifications. The combination of a 6% native gel and a decreased electrophoresis temperature permits multiple uses of a given gel with consistent

Table 3. Comparison of the averaged separation time of PCR products with the same size in 6% native gels used different times

Number of usage	Averaged separation time (min) for PCR products with the same size (bp)		
	100–112	142–158	210–227
1	37.0	46.0	58.5
2	37.0	45.0	58.0
3	37.0	45.5	58.0
4	36.5	45.0	57.5
P	>0.05	>0.05	>0.05

A 6% native gel was subjected to electrophoresis four times under 45°C for the same PCR mixtures. The averaged separation time, in 3–4 separate sets of electrophoresis, of the PCR product with the same size at different runs was statistically compared with the F-test.

results, consequently reducing the electrophoresis time and reagent costs.

The authors greatly appreciate Daniel Wheatley, M. S., the statistician of The Armed Forces Institute of Pathology, for performing the statistical analysis. The authors are also very grateful to Dr. Zong-mei Sheng of Department of Cellular Pathology of AFIP, for critically reviewing the manuscript. This study is partially supported by an in-house grant (grant number 2207) from the American Registry of Pathology, and a New Concept Award for fiscal year 2000 from Congressionally Directed Breast Cancer Program.

Received November 17, 2000

Table 4. Comparison of the relative mobilities of PCR products in 6% native gels used once and multiple times

Number of usage	Relative mobility of PCR products with the same size (bp)		
	100–112	142–158	210–227
1	0.60–0.56	0.43–0.40	0.15–0.10
2	0.59–0.57	0.43–0.41	0.15–0.10
3	0.61–0.58	0.45–0.42	0.17–0.13
4	0.61–0.58	0.46–0.43	0.18–0.15
P	>0.05	>0.05	>0.05

A 6% native gel was subjected to electrophoresis four times under 45°C for the same PCR mixtures. The averaged relative mobility, in 3–4 separate sets of electrophoresis, of the PCR products with the same size at different runs was statistically compared with F-test.

References

- [1] Man, Y. G., Moinfar, F., Brathauer, G. L., Tavassoli, F. A., *Diagn. Mol. Pathol.* 2000, 9, 84–90.
- [2] McEvoy, C. R., Seshadri, R., Firgaira, F. A., *BioTechniques* 1998, 25, 464–470.
- [3] Man, Y. G., Moinfar, F., Brathauer, G. L., Kuhls, E. A., Tavassoli, F. A., *Pathol. Res. Practice* 2001, in press
- [4] Moinfar, F., Man, Y. G., Brathauer, G. L., Ratschek, M., Tavassoli, F. A., *Cancer* 2000, 88, 2072–2081.
- [5] Moinfar, F., Man, Y. G., Arnould, L., Brathauer, G. L., Ratschek, M., Tavassoli, F. A., *Cancer Res.* 2000, 60, 2562–2566.
- [6] Mooney, E. E., Man, Y. G., Brathauer, G. L., Tavassoli, F. A., *Cancer* 1999, 86, 2312–2319.